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newly encountered epitopes. This reflects
competition for antigen accessibility on
antigen-presenting cells that suppresses
the priming of protective pathogen-
specific CD8+ T cells.
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Despite robust secondary T cell expansion primed
by vaccination, the impact on primary immune re-
sponses to heterotypic antigens remains unde-
fined. Here we show that secondary expansion of
epitope-specific memory CD8+ T cells primed by
prior infection with recombinant pathogens limits
the primary expansion of naive CD8+ T cells with
specificity to new heterologous antigens, dampening
protective immunity against subsequent pathogen
challenge. The degree of naive T cell repression
directly paralleled the magnitude of the recall
response. Suppressed primary T cell priming reflects
competition for antigen accessibility, since clonal
expansion was not inhibited if the primary and sec-
ondary epitopes were expressed on different den-
dritic cells. Interestingly, robust recall responses
did not impact antigen-specific NK cells, suggesting
that adaptive and innate lymphocyte responses
possess different activation requirements or occur
in distinct anatomical locations. These findings
have important implications in pathogen vaccination
strategies that depend on the targeting of multiple
T cell epitopes.INTRODUCTION
The safety and protective efficacy of vaccination using intracel-
lular microbial vectors, such as recombinant Listeria monocyto-
genes, adenovirus, or vaccinia virus engineered to contain CD8+
T cell epitopes, is well documented (Weiskirch and Paterson,
1997; Koup and Douek, 2011; Orr et al., 2007). Many of these
vaccination strategies aim to generate large numbers of memory
CD8+ T cells that are capable of mounting a robust and pro-
tective recall response during future infection. Although the gen-
eration of more accelerated and robust secondary responses
is typically considered to be beneficial, cross-reactivity of vac-636 Cell Reports 17, 636–644, October 11, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://cine-elicited CD8+ T cells can negatively impact naive immune
responses to variants of the targeted epitopes encountered dur-
ing an actual pathogen exposure, a phenomenon previously
termed ‘‘original antigenic sin.’’ Although this phrase was first
described in the setting of humoral responses against repeated
exposure to influenza (Davenport et al., 1953; Fazekas de St.
Groth and Webster, 1966; Kim et al., 2009), this phenomenon
has also been observed in recall CD8+ T cell responses against
variants of lymphocytic choriomeningitis virus (LCMV) in mice
and dengue virus in humans (Klenerman and Zinkernagel,
1998; Mathew and Rothman, 2008; Mongkolsapaya et al.,
2003). The prevailing explanation for original antigenic sin is
that large numbers of pre-existing memory cells can suppress
the small numbers of naive immune cells responding to variants
of the priming antigen. However, a recent study showing that
low-avidity memory CD8+ T cells, even at extremely high precur-
sor frequency, did not suppress high-avidity naive CD8+ T cells
suggests that this phenomenon may be limited to instances
where the memory CD8+ T cells have a high avidity for the prim-
ing epitopes (Zehn et al., 2010).
Nonetheless, all of these prior studies describe how naive
T cells may be competing with memory T cells against the
same epitope or epitope variant. To the best of our knowledge,
how a large epitope-specific recall response impacts new het-
erotypic T cell responses remains undefined. Here we utilize a
prime-boost strategy to investigate the influence that immuno-
dominant memory CD8+ T cell populations may have on the
priming of both adaptive and innate lymphocyte responses.RESULTS
Vaccination with Recombinant Listeria monocytogenes
Suppresses Naive Heterologous Responses after MCMV
Challenge
To investigate how pre-existing memory CD8+ T cells may affect
the generation of heterologous naive T cell responses, we first
engineered recombinant Listeria monocytogenes (Lm) strains
that expressed the CD8+ T cell epitopes found in mouse cyto-
megalovirus (MCMV)-encoded M45 (amino acids 985–993,
Lm-M45) and M38 (amino acids 316–323, Lm-M38). These two.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Previous Priming with Recombinant Lm Generates Large Recall CD8+ T Cell Responses following MCMV Challenge that Limit
Heterologous CD8+ T Cell Responses
(A) Schematic shows CD8+ T cell prime-boost strategy against MCMV-specific epitopes.
(B and C) Percentage and absolute number of epitope-specific CD8+ T cells in the spleen were determined by tetramer staining at day 7 following MCMV
challenge in mice vaccinated with Lm-M38 (B) or Lm-M45 (C) 4–6 weeks earlier.
(legend continued on next page)
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epitopes previously have been shown to drive robust CD8+ T cell
responses during MCMV infection (Munks et al., 2006), and
they were thus attractive candidates for vaccination. To confirm
that these Lm strains were effective tools for generating memory
CD8+ T cell populations, we immunized C57BL/6 mice with
Lm-M45 or Lm-M38 and challenged them 4–6 weeks later with
MCMV (Figure 1A). Antigen-specific CD8+ T cell responses
were measured using peptide/major histocompatibility complex
class I (MHC class I) tetramers (Munks et al., 2006), in conjunc-
tion with intracellular IFN-g staining after peptide stimulation
(data not shown). Infection with recombinant Lm produced
epitope-specific CD8+ T cell responses that peaked at day 7
post-infection (PI), followed by contraction to form a stable
memory pool (data not shown).
Following MCMV challenge in mice previously infected with
Lm-M38 (Figure 1B) or Lm-M45 (Figure 1C), we observed
enhanced epitope-specific memory CD8+ T cell responses
compared to mice given PBS during initial priming. To investi-
gate the impact of these M45- or M38-specific recall CD8+
T cell responses on heterologous naive CD8+ T cell responses
generated during MCMV infection, we measured the M38-spe-
cific CD8+ T cell response in the cohort previously vaccinated
with Lm-M45 or, reciprocally, the M45-specific CD8+ T cell
response in animals previously vaccinated with Lm-M38. Inter-
estingly, we found that the naive heterologous responses (i.e.,
M45-specific CD8+ T cell response in Lm-M38 primed mice
and M38-specific CD8+ T cell response in Lm-M45 primed
mice) elicited by MCMV in these vaccinated animals were dimin-
ished compared to animals that had been mock-immunized with
PBS (Figures 1B and 1C). This suppression of new CD8+ T cell
responses in the spleen also was observed in other tissues,
such as blood and liver (Figure S1A). Thus, immunization of
mice with recombinant Lm successfully generated epitope-spe-
cific memory CD8+ T cells, which, when recalled, correlated with
diminished heterologous primary CD8+ T cell responses.
DuringMCMV infection, a subset of natural killer (NK) cells can
respond specifically to the viral glycoprotein m157 through the
activating receptor Ly49H (Arase et al., 2002). TheseMCMV-spe-
cific NK cells recently have been shown to exhibit many adaptive
immune features, including antigen specificity, clonal expansion,
long-lived memory, and recall responses during MCMV infection
(Sun and Lanier, 2011). Therefore, we also investigatedwhether a
large secondary CD8+ T cell responsemight influence the gener-
ation of an antigen-specific primary NK cell response during viral
infection.Usingapreviously describedexperimental system (Sun
et al., 2009), we adoptively transferred Ly49H+ NK cells into
Ly49H-deficient hosts previously infected with Lm-M45 (or
PBS), and then we challenged them with MCMV (Figure S1B).
FollowingMCMV challenge, M45-specific CD8+ T cell responses(D) Ly49H-deficient mice that had been primed with Lm-M45 4–6 weeks prior rece
Percentages of M45-specific CD8+ T cells and Ly49H+ NK cells in spleen were
challenged with MCMV served as a control for all experiments (A–D).
(E) Mice were primed with Lm-Ova (or PBS as a control) and subsequently chal
responses were measured in the spleen at day 7 after challenge.
(F) Mice were primed with MCMV (or PBS as a control) and challenged 4–6 week
in the spleen at day 7 following challenge. Bars represent mean ± SEM; n R 3
**p < 0.01, and ***p < 0.001.
638 Cell Reports 17, 636–644, October 11, 2016were significantly larger in Lm-M45-primed mice compared
with PBS-primed mice (Figure 1D; Figure S1C); however, unlike
heterologous naive CD8+ T cell responses, which also were sup-
pressed in these studies (data not shown), the Ly49H+ NK cell
population proliferated and expanded in amanner that was inde-
pendent of the presence or magnitude of the M45-specific CD8+
T cell recall response (Figure 1D; Figure S1C). Thus, robust recall
CD8+ T cell responses have no impact on NK cell activation or
proliferation, and they suggest either differential priming require-
ments or compartmentalized priming of innate versus adaptive
lymphocytes following viral challenge.
To confirm that the suppressed clonal expansion of heterolo-
gousnaiveCD8+Tcells byprolific recall responseswasnot limited
toepitopes found inM45andM38,micewereprimedwithLm-Ova
(ovalbumin) and challenged with MCMV-Ova 30 days later. In
these studies, a large secondary CD8+ T cell response specific
to Ova (SIINFEKL) suppressed a primary CD8+ T cell response
to M45 (Figure 1E), and this diminished response measured at
day 7 PI was not due to delayed kinetics, as the M45-specific
CD8+ T cell numbers contracted on a similar timescale in control
and suppressed mice (data not shown). In separate experiments,
diminishedexpressionofNur77,CD69, andCD25wasobserved in
the suppressedCD8+ T cells early after infection (Figures S1D and
S1E), suggesting that the suppressed T cells do not receive the
same quality of T cell receptor (TCR) signal or degree of activation
as the control T cells (Moran et al., 2011), even thoughbothgroups
are encountering antigen and undergoing clonal proliferation.
Furthermore, to demonstrate that suppression of naive heter-
ologous CD8+ T cells by a recall response was not restricted
to bacteria priming followed by virus boost, we primed mice
with MCMV (or PBS) first, followed by challenge with Lm-M45
6 weeks later. Because Lm-M45 also carries the Ova epitope
and Lm encodes the endogenous fMIGWII epitope, which is pre-
sented on the non-classical MHC class I molecule H2-M3 (Lenz
et al., 1996), these two epitopes represent the primary CD8+
T cell responses, whereas the M45 epitope represents the recall.
In this prime-boost scheme, we observed that the large M45-
specific recall CD8+ T cell response in the animals pre-treated
with MCMV correlated with significantly diminished primary
Ova- and fMIGWII-specific CD8+ T cell responses in all organs
compared to PBS controls (Figure 1F; Figure S1F). Together
these findings suggest that the inhibition of primary heterologous
CD8+ T cell responses by a robust recall response is neither
dependent on the type of pathogen nor the type of MHC class I.
The Overall Size of Recall Determines the Degree of
Heterologous CD8+ T Cell Suppression
Having observed that large secondary CD8+ T cell responses
were able to suppress heterologous primary responses duringived adoptively transferred Ly49H+ NK cells and were challenged with MCMV.
measured at day 7 following MCMV challenge. Mice primed with PBS and
lenged with MCMV-Ova 4–6 weeks later. Ova- and M45-specific CD8+ T cell
s later with Lm-M45. Epitope-specific CD8+ T cell responses were measured
per replicate; data are representative of three to four experiments; *p < 0.05,
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Figure 2. The Size of Recall Response Cor-
relates with Degree of Heterologous CD8+
T Cell Suppression
(A and B) Mice were primed with 2, 1, or 0 Lm
strains and then challenged with MCMV-Ova
4–6weeks later. Percentages of recalledM38- and
Ova-specific CD8+ T cells (A) or primary M45-
specific CD8+ T cells (B) in the spleen are shown
for day 7 after challenge.
(C and D) The 10-fold dilutions of memory OT-I
CD8+ T cells (CD45.1) were transferred into WT
mice (CD45.2), and mice were challenged with
MCMV-Ova. Percentages of recalled OT-I cells
(C) or primary M45-specific CD8+ T cells (D) are
shown for day 7 following challenge.
(E) WT mice were primed with MCMV (or PBS as a
control), infected 4–6 weeks later with Lm-M45 +
Lm-M38 (both containing Ova), and challenged
4–6 weeks later with Lm-Ova. Lm-Ova colony-
forming units (CFUs) in spleen and liver of both
groups of mice were determined at day 2 following
challenge. Bars represent mean ± SEM; n R 3
per replicate; data are representative of two to
four experiments; *p < 0.05, **p < 0.01, and ***p <
0.001.MCMV challenge, we asked whether the size of that recall
response might dictate the degree of primary CD8+ T cell sup-
pression. To address this question, we primed one group of
mice with Lm-Ova plus Lm-M38, another group with Lm-Ova
alone, and a third group with PBS. This strategy generated three
groups with titrated numbers of antigen-specific memory CD8+
T cells (Figure S2A), which were reflected in a scaled recall
response in all organs following challenge with MCMV-Ova (Fig-
ure 2A; Figure S2B). In agreement with our previous data, the
groups with antigen-specific recall CD8+ T cell responses
potently suppressed the primary M45-specific CD8+ T cell
response compared to the PBS-treated group (Figure 2B; Fig-
ure S2B). Notably, the group primed with both Lm-Ova and
Lm-M38 showed a greater degree of suppression than the group
primed with Lm-Ova alone (Figure 2B; Figure S2B), suggesting
that the overall size of the recall correlates with the amount of
suppression observed in the primary heterologous CD8+ T cell
response.Cell RAs an alternative approach, we trans-
ferred different numbers of memory
OT-1 CD8+ T cells (containing a TCR spe-
cific to the Ova epitope) into mice and
challenged with MCMV-Ova. (Memory
OT-I cells were generated by adoptive
transfer of naive CD45.1+ OT-1 into
CD45.2+ wild-type (WT) mice followed
by Lm-Ova infection; 30 days later,
spleens were harvested and CD8+ OT-1
cells were sorted and transferred). On
day 7 following MCMV-Ova challenge,
titrated recall OT-1 responses were
observed in spleen and multiple periph-
eral organs (Figure 2C; Figure S2C).Consequently, the degree of suppression of the primary M45-
specific CD8+ T cell response correlated with the magnitude of
the recall OT-1 response (Figure 2D; Figure S2C), consistent
with a previous study that investigated the impact of naive
P14 on endogenous CD8+ T cells responding to different
LCMV epitopes (Butz and Bevan, 1998). Although these findings
are restricted by the transgenic mice and recombinant patho-
gens currently available, they broadly suggest that the size of
recall responses plays an important role in the degree of
suppression observed in primary heterologous CD8+ T cell
responses against pathogens.
Suppression of CD8+ T Cell Responses Impacts
Pathogen Load during Challenge
To investigate the impact of suppressed CD8+ T cell responses
during repeated pathogen exposure, susceptibility to infection
was determined in animals where naive CD8+ T cell responses
were suppressed by heterologous recall responses. WT miceeports 17, 636–644, October 11, 2016 639
were primed with MCMV (or PBS as a control) and 30 days later
challenged with Lm-M45 + Lm-M38 (which both contain Ova).
Similar to the findings in Figure 1F, robust M45- and M38-spe-
cific recall responses suppressed the primary Ova-specific
CD8+ T cell response in MCMV-primed, but not PBS-primed,
mice (data not shown). Next, these primed mice were given a
third injection 30 days later with Lm-Ova, and bacterial titers
(colony-forming unit [CFU]) were determined after challenge. In
mice where the Ova-specific CD8+ T cell response previously
had been suppressed (MCMV infection followed by Lm-M45 +
Lm-M38), sharply increased bacterial titers were recovered
from the spleen and liver compared with control mice (PBS
followed by Lm-M45 + Lm-M38) following bacteria challenge
(Figure 2E), demonstrating that the heterologous suppres-
sion of naive CD8+ T cell clonal expansion during epitope-spe-
cific vaccination can have detrimental consequences to host
immunity.
Naive CD8+ T Cell Suppression Is Not due to Lack of
Antigen Availability
We next sought to determine the underlying mechanisms behind
the heterologous CD8+ T cell suppression. To rule out the possi-
bility that theantigen-specific recall responsewassimply clearing
infected cells more effectively and thus eliminating antigen avail-
able for optimal priming of new naive CD8+ T cells, we evaluated
viral titers throughout the course of MCMV challenge in the blood
of Lm-primed and PBS-primed mice. We observed no differ-
ences in the amount of virus in blood and organs regardless of
prior immunization with Lm expressing either CD8+ T cell epitope
from MCMV (Figures 3A and 3B), suggesting that loss of antigen
availability is not the cause of primary CD8+ T cell suppression
during a recall response. The similar viral titers observedbetween
the two groups of mice may be due to the multiple immune
evasion strategies employed by MCMV (Sun and Lanier, 2009).
Although previous studies have demonstrated that a short
exposure to antigen is sufficient to drive a productive CD8+
T cell response (Kaech and Ahmed, 2001; van Stipdonk et al.,
2001), we nevertheless wanted to confirm that antigen availabil-
ity over time was not an important factor in primary CD8+ T cell
suppression in our prime-boost studies. Using a replication-defi-
cient Listeria strain, Lm-M45(DActA), the amount and duration of
antigen should be comparable between groups, as there would
be limited antigen presentation on antigen-presenting cells
(APCs). Thus, we first primed mice with MCMV and then chal-
lenged with ActA-deficient Lm-M45 (which also contains the
Ova epitope). Although the M45-specific recall response was
weak (likely due to the replication-deficient Lm), the primary
CD8+ T cell response to Ova was still suppressed in MCMV-
primed mice compared to the control group (Figure 3C; Fig-
ure S3A). Similarly, transfer of memory OT-1 followed by chal-
lenge with Lm-M45 and treatment with ampicillin at days 1, 3,
and 5 PI (which efficiently eradicated Lm in target tissues) (Wil-
liams and Bevan, 2004) resulted in a robust Ova-specific recall
response but suppression of the M45-specific primary response
(Figure 3D; Figure S3B). Taken together, these results suggest
that overall antigen availability is not the determining factor in
the suppression of primary CD8+ T cell responses by large recall
responses during pathogen challenge.640 Cell Reports 17, 636–644, October 11, 2016Naive CD8+ T Cell Suppression Is due to Competition for
Antigen Access on APCs
We next investigated whether competition with memory cells for
antigen access on APCs was restricting the primary CD8+ T cell
response. First, we attempted to block the ability of OT-1 cells
to see antigen on APCs by using an antibody against MHC class
I/SIINFEKL complexes (Porgador et al., 1997; Blair et al., 2011).
Following OT-1 transfer and challenge with MCMV-Ova, one
group of mice received SIINFEKL-blocking antibody at days 0,
2, and 4 PI, whereas another group received control IgG anti-
body. The SIINFEKL-blocking antibody partially inhibited the
OT-1 response during infection, resulting in a partial rescue of
the primary CD8+ T cell response toM45 (Figure 4A; Figure S4A),
suggesting that limiting the expansion of memory CD8+ T cells
can reduce suppression of heterologous primary CD8+ T cell
responses.
To further address the question of antigen accessibility,
we primed mice with Lm-M45, and then we challenged them
30 days later with bone marrow-derived dendritic cells (BMDCs)
co-pulsed or separately pulsed with M38 and M45 peptide. (The
M38 peptide is presented by H2-Kb whereas the M45 peptide is
presented by H2-Db, thereby eliminating competition of peptide
binding for the same MHC class I.) In the separately pulsed DC
group, the priming of the secondary response (M45) was distinct
from the primary response (M38) at the level of the APC. When
previously immunized mice were challenged with BMDCs that
had been co-pulsed with both peptides, such that both epitopes
are presented by the same DC, the primary M38-specific CD8+
T cell response was suppressed by the recall M45 response (Fig-
ure 4B). However, immunized mice challenged with separately
pulsed BMDCs showed a more robust M38-specific CD8+
T cell expansion, rescued fully in the blood and partially in the
spleen (Figure 4B), providing further evidence that competition
for antigen presented by APCs is responsible for the suppression
of primary heterologous responses by recall responses.
Finally, we generatedmixed bonemarrow chimeric mice using
bone marrow from Kb/Db/mice and H2-M3/mice, where
half of the hematopoietically derived DCs were able to present
M3/fMIGWII following Listeria infection and the other half were
able to present MCMV-specific peptides of interest concurrently
with Ova (SIINFEKL) on Kb or Db, but neither population of DCs
was able to present all epitopes (Figure S4B). These mixed
chimeric mice were primed with MCMV or PBS and then chal-
lenged with Lm-M45 5 weeks later. In MCMV-primed mice, the
large M45-specific recall response suppressed the primary
Ova-specific response in all organs compared to PBS-primed
controls (Figure 4C; Figure S4C). However, no suppression of
the primary M3/fMIGWII-specific response was observed in
MCMV-primed chimeric mice (Figure 4C; Figure S4C), demon-
strating naive heterologous CD8+ T cells can respond optimally
if they are not competing with memory CD8+ T cells for access
to antigen on the same APC.
DISCUSSION
In this study, we provide evidence for immune suppression
mediated by recall CD8+ T cell responses where heterologous
naive CD8+ T cell populations are unable to proliferate to their
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Figure 3. SuppressedCD8+ T Cell Response
in Primed Mice following Pathogen Chal-
lenge Is Independent of Pathogen Titer
(A and B) MCMV titers are shown in the blood at
various time points (A) and in relevant organs at
day 3 PI (B) from Lm-M38- or Lm-M45-primed
mice, followed by MCMV challenge 4–6 weeks
later.
(C) Mice were primed with MCMV and then chal-
lenged with Lm-M45(DActA) 4–6 weeks later.
Percentages of secondary M45-specific CD8+
T cell responses and primary Ova-specific CD8+
T cell responses are shown for the spleen at day 7
after challenge.
(D) The 105 memory OT-I cells (CD45.1) were
transferred into WT mice (CD45.2), mice were in-
fected with Lm-M45 (also containing Ova epitope),
and they were treated with ampicillin at days 1, 3,
and 5 PI. Percentages of secondary Ova-specific
CD8+ T cell responses and primary M45-specific
CD8+ T cell responses are shown for the spleen at
day 7 PI. Bars represent mean ± SEM; n R 3 per
replicate; data are representative of two to four
experiments; *p < 0.05, **p < 0.01, and ***p < 0.001.full potential. This observed suppression is in part due to
decreased antigen access on APCs, likely because small
numbers of naive CD8+ T cells are crowded out by the large pop-
ulation of memory CD8+ T cells. The competition of naive and
memory T cells for access to the APCs also may result in differ-Cell Rential interactions with co-stimulatory
molecules on the APC surface, in addi-
tion to MHC and antigen. Furthermore,
a larger overall recall response led to
greater suppression of new heterologous
responses. Our findings build on our cur-
rent understanding of cross-competition
during primary infection, and they provide
a new model of clonal competition be-
tween heterologous memory and naive
T cells, whereas previous studies on
CD8+ T cell competition relied on antigen
affinity for a given epitope (Kedl et al.,
2000; Smith et al., 2000; Grufman et al.,
1999; Kedl et al., 2002). Although our
findings resemble the results from orig-
inal antigenic sin papers in that new
responses are inhibited by anamnestic
responses, the previous studies demon-
strate suppression of the same (or similar)
epitopes, whereas we now demonstrate
suppression of heterologous immune
responses.
Interestingly, large secondary CD8+
T cell responses had no impact on the
expansion of MCMV-specific NK cells.
Previous studies have suggested that
APC engagement by NK cells during
MCMV is needed for optimal activation(Degli-Esposti and Smyth, 2005; Krug et al., 2004); however,
the current study provides evidence that antigen presentation
(of viral m157) may not be restricted to professional APCs and
that NK cells may not need to see antigen on professional
APCs for their priming, as MCMV is also known to infecteports 17, 636–644, October 11, 2016 641
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Figure 4. Competition for MHC Class I Access on APCs Dictates Suppression of Naive Heterologous CD8+ T Cells by Recall Response
(A) Mice received 105 OT-I cells (CD45.1) and were infected with MCMV-Ova while also receiving an anti-Kb/SIINFEKL antibody or control IgG at days 0, 2, and
4 PI. Percentages of secondary Ova- and primary M45-specific CD8+ T cell responses in the spleen are shown at day 7 PI.
(B) Mice were primed with Lm-M45 and then challenged 30 days later with indicated peptide-pulsed BMDCs. Percentages of secondary M45- and primary M38-
specific CD8+ T cell responses in the spleen and blood are shown at day 7 following DC injection.
(C) MixedM3/:Kb/Db/ bonemarrow chimeric mice were primedwithMCMV or PBS and challenged 5weeks later with Lm-M45. Percentages of secondary
M45- and primary Ova- or M3-specific CD8+ T cell responses in the spleen are shown at day 7 following Lm-M45 challenge. Bars represent mean ± SEM; nR 3
per replicate; data are representative of two to four experiments; *p < 0.05, **p < 0.01, and ***p < 0.001.monocytes, hepatocytes, or endothelial cells (Shellam et al.,
2006). An alternative hypothesis could be that differential
kinetics of m157 expression compared to processing/presenta-
tion of viral peptides on MHC class I may explain why MCMV-
specific NK cells are not inhibited by antigen-specific memory
CD8+ T cells. Furthermore, naive T and NK cells may be primed
at anatomically distinct sites, with naive CD8+ T cells competing642 Cell Reports 17, 636–644, October 11, 2016with central memory CD8+ T cells in draining lymph nodes,
whereas NK cells may compete with effector memory CD8+
T cells in the spleen and liver. None of these explanations are
mutually exclusive, and further investigation is required to deter-
mine whether location or timing of antigen presentation can ac-
count for the differences in suppression between naive T cells
versus NK cells mediated by the recall response.
Our overall findings using mice primed with specific recom-
binant pathogens suggest that vaccination strategies where indi-
viduals are primed against a specific CD8+ T cell epitope (or set
of epitopes) can in certain circumstances impede new T cell
responses to a given pathogen of interest, and they can be detri-
mental during subsequent pathogen encounter. Although the
epitopes investigated in our study all represent immunodomi-
nant T cell epitopes, our findings are consistent with a compan-
ion study in which the degree of suppression of naive heterotypic
CD8+ T cell responses by robust recall responses correlates
with affinity of the ligand (Oberle et al., 2016 [this issue of Cell
Reports]), and they suggest that even greater suppression of
heterotypic clonal expansion in our system (than what we have
measured) may be occurring within subdominant T cell popula-
tions. Additionally, a previous study suggested that pre-existing
anti-viral immune memory to epitopes naturally expressed by
adenovirus resulted in the decreased effectiveness in priming
new heterologous CD4+ and CD8+ T cell responses in individuals
when using adenoviral vectors expressing HIV proteins (Frahm
et al., 2012). We believe our current findings may provide an
explanation for this observation, and they may inform current
and future vaccine strategies that involve epitope-specific prim-
ing of T cell responses against pathogens such as HIV, malaria,
and tuberculosis.
EXPERIMENTAL PROCEDURES
Mice and Chimeras
All mice used in this study were bred andmaintained at Memorial Sloan Ketter-
ing Cancer Center (MSKCC) in accordance with the Institutional Animal Care
and Use Committee. Mice were immunized at 6–10 weeks of age. In certain
experiments, WT CD45.1 mice were lethally irradiated (900 Gy), and they
were injected with a 1:1 mixture of bone marrow fromM3-deficient (kindly pro-
vided by Dr. Chyung-RuWang, Northwestern University) and Kb/Db/mice
(kindly provided by Dr. Ming Li, MSKCC). Then 8weeks following bonemarrow
reconstitution, chimeric mice were immunized.
Bacterial and Viral Infections
Recombinant Listeria monocytogenes expressing MCMV- and Ova-derived
epitopes were generated as previously described (Orr et al., 2007). Lm-M45
and Lm-M38 were grown in brain-heart infusion (BHI) plus 10 mg/mL chloram-
phenicol until mid-log phase, and Lm-Ova was grown in BHI plus 1 mg/mL
erythromycin, before dilution in PBS to appropriate concentration for injection.
Unless indicated, mice were infected with 104 CFUs of Lm intravenously. In
certain co-infection experiments, 5 3 103 CFUs of each Lm strain was used.
In certain challenge experiments, 2 3 105 CFUs of recombinant Lm strains
were used. A dose of 106 CFUs was used for Lm-M45(DActA). Bacterial titers
were determined in organs by plating on BHI plates containing 1 mg/mL eryth-
romycin, as previously described (Sun and Bevan, 2003).
MCMV (Smith strain) was passaged serially through BALB/c mice two to
three times, and viral stocks were prepared from salivary glands. MCMV-
Ova was prepared in culture using NIH 3T3 cells. Mice were infected with
7.5 3 103 plaque-forming units (PFUs) by intraperitoneal injection. In NK cell
transfer experiments, recipient Ly49H-deficient mice were infected with
7.5 3 102 PFUs of MCMV 1 day after receiving 5 3 105 purified splenic
Ly49H+ NK cells.
Flow Cytometry Analysis
Single-cell suspensions were generated from the various organs and stained
with the indicated fluorophore-conjugated antibodies (BD Biosciences,
eBioscience, BioLegend, and Tonbo). MHC class I tetramers were gener-
ated by conjugating Kb/SIINFEKL (Ova), Kb/SSPPMFRV (M38), or Db/HGIR-
NASFI (M45) monomers (NIH Tetramer Facility) to streptavidin-phycoery-thrin (BD Biosciences/Life Technologies). The M3/fMIGWII tetramer was
kindly provided by Dr. Eric Pamer (MSKCC). Flow cytometry was performed
on an LSR II cytometer (Becton Dickinson), cells were sorted on an Aria
(Becton Dickinson), and data were analyzed with the FlowJo software
(Tree Star).
Adoptive Transfers
NK cells were enriched by removing T, B, and red blood cells from total
splenocyte suspensions using rat IgG against mouse CD4, CD8, CD19,
and Ter119 (University of California at San Francisco Core Facility, 10 mg
of each antibody per spleen), followed by anti-rat IgG-coupled magnetic
beads (QIAGEN) and magnetic depletion. Approximately 5 3 105 enriched
NK cells were injected intravenously into recipient mice 1 day before MCMV
infection.
Memory OT-I CD8+ T cells were isolated by tetramer staining and
cell sorting (greater than 99% purity), and the indicated amount of cells was
injected intravenously into recipients prior to infection. In certain experiments,
500 mg/mouse of an anti-Kb/SIINFEKL antibody (clone 25-D1-16, Bio X Cell) or
control IgG1 (clone MOPC-21, Bio X Cell) was administered intraperitoneally
on days 0, 2, and 4 following infection with MCMV-Ova.
DCs were prepared by isolating primary bone marrow from WT mice and
culturing in complete RPMI + 10% fetal bovine serum (FBS) and 20 ng/mL
granulocyte macrophage colony-stimulating factor (GM-CSF) for 6 days.
Following 6 days of culture, a cocktail of Toll-like receptor (TLR) ligands
(2 mg/mL CpG + 10 mg/mL Poly I:C) was added overnight to induce maturation,
and relevant peptide was added to culture at a concentration of 500 ng/mL for
2 hr before injection. Mice were injected subcutaneously with 106 peptide-
pulsed BMDCs.
Viral qRT-PCR
DNA was isolated from indicated organs using a genomic purification kit
(QIAGEN). Following isolation, DNA concentration was measured using
Nanodrop for each sample, and 3 mL was added into mastermix containing
iQ Sybr Green (Bio-Rad) and primers specific to MCMV DNA (forward:
TCGCCCATCGTTTCGAGA and reverse: TCTCGTAGGTCCACTGACCGA).
Copy number was determined by comparing Cq values to a standard curve
of known dilutions of an MCMV plasmid.
Statistical Analysis
Results are presented as mean, with error bars representing ±SD. Data were
analyzed on GraphPad Prism 6 software using a two-tailed paired Student’s
t test without standard scatter assumptions, and differences were considered
significant at p values of less than 0.05.
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